Results 91 to 100 of about 22,112 (155)

Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3. [PDF]

Theranostics
Glazer SE, Sutton MN, Yang P, Pisaneschi F, Sebastian M, Gammon ST, Piwnica-Worms D.   +6 more
europepmc   +1 more source

Enhanced renal ischemia/reperfusion injury repair potential of exosomes derived from B7-H1^high mesenchymal stem cells. [PDF]

Front Genet
He J, Yao Y, Wang R, Liu Y, Wan X, Wang H, Zhou Y, Wang W, Ma Y, Lv X.   +9 more
europepmc   +1 more source

The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy. [PDF]

J Exp Clin Cancer Res
Hussein OJ, Rayan M, Matarid TR, Elkhalifa D, Abunada HH, Therachiyil L, Khalil A, Uddin S, Maccalli C, Korashy HM.   +9 more
europepmc   +1 more source

Salvage Surgery Following Definitive Chemoradiotherapy and Immune Checkpoint Inhibitor Therapy for Locally Advanced Thymic Carcinoma. [PDF]

Interdiscip Cardiovasc Thorac Surg
Tokuda R, Ikebe S, Nishimura-Hanafusa S, Inoue M.   +3 more
europepmc   +1 more source

Moving beyond cytotoxicity in cancer immunotherapy: embracing tumor microenvironment remodeling for durable control. [PDF]

Br J Cancer
Koelsch N, Manjili MH.
europepmc   +1 more source

Assessment of Programmed Cell Death Ligand-1 Expression in Oral Potentially Malignant Disorders and Tumor-Free Surgical Margins of Oral Squamous Cell Carcinoma: Protocol for a Retrospective Cross-Sectional Study.

JMIR Res Protoc
Sonone A, Hande A, Patil S, Pakhale A, Sharma P.   +4 more
europepmc   +1 more source

Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment. [PDF]

NPJ Precis Oncol
Marchesi S, Marinello A, Ambrosini P, Cavalli C, Lo Russo G, Occhipinti M.   +5 more
europepmc   +1 more source

Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy. [PDF]

Immunotargets Ther
Liu Q, Li L, Nian S, Sun X, Guo X, Li C, Yang Z, Ye Y, Yuan Q.   +8 more
europepmc   +1 more source

Discrepant CD3+ TILs in PD-L1-Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy. [PDF]

Am J Case Rep
Sekiya M, Nakatsugawa M, Koyama N, Kajiwara N, Aoki T.   +4 more
europepmc   +1 more source

Crosstalk between tumor-associated macrophages and the B7/CD28 family in immune checkpoint inhibitor-induced immunotherapy. [PDF]

Mol Cell Biochem
Bai R, Sun W.
europepmc   +1 more source